Navigation Links
Kosan Opens Registration Program for Lead Hsp90 Inhibitor, Tanespimycin, in Multiple Myeloma
Date:8/19/2007

sly reported, 44% (18 out of 41 patients evaluable for response). Of the 44%, 8 out of 14 patients were bortezomib-nave (57%); 7 out of 16 patients were bortezomib-pretreated patients (44%); and 3 out of 11 patients were bortezomib-refractory (27%). Responses in the bortezomib-refractory patients continue to show prolonged duration (at least 10 months at the time of data presentation at ASCO in June 2007) and meaningful reduction of serum/urinary M-protein (greater than 89%). The combination of tanespimycin and bortezomib was well-tolerated.

Kosan has been granted orphan drug designation for tanespimycin in multiple myeloma in both the US and European Union.

About Kosan

Kosan Biosciences is a biotechnology company advancing two new classes of anticancer agents through clinical development -- Hsp90 (heat shock protein 90) inhibitors and epothilones. Kosan is leveraging its proprietary discovery platform to generate a pipeline of potentially significant product candidates, primarily in the area of oncology.

Hsp90 inhibitors have a novel mechanism of action targeting multiple pathways involved in cancer cell growth and survival. Tanespimycin (KOS-953) is being tested in combination with bortezomib in patients with multiple myeloma in a registration program called TIME. Tanespimycin is also being studied in multiple myeloma as monotherapy, in HER2-positive metastatic breast cancer in combination with Herceptin, and as monotherapy in metastatic melanoma. Intravenous and oral formulations of Kosan's second-generation Hsp90 inhibitor, alvespimycin (KOS-1022), are being evaluated in Phase 1 clinical trials in hematological cancers and in HER2-positive metastatic breast cancer.

Epothilones inhibit cell division with a mechanism of action similar to taxanes, one of the most successful classes of anti-tumor agents. KOS-1584 is in Phase 1 clinical trials in patients with solid tumors. Kosan's epothilone program is partnered with Roche through a glo
'/>"/>

SOURCE Kosan Biosciences Incorporated

Copyright©2007 PR Newswire.

Page: 1 2 3 4 5 6

Related medicine technology :

1. Kosan Presents Promising Phase 1 Data on Second-Generation Hsp90 Inhibitor, Alvespimycin, Showing Antitumor Activity in Refractory Breast and Ovarian Cancers at ASCO
2. Kosan Presents Phase 1 Data Showing Promising Antitumor Activity and Safety Profile of Epothilone KOS-1584 at ASCO
3. Kosan Presents Data on Lead Hsp90 Inhibitor, Tanespimycin, Showing Promising Antitumor Activity in Multiple Myeloma at ASCO
4. Kosan Presents Preliminary Phase 2 Data Showing Antitumor Activity of Hsp90 Inhibitor Tanespimycin in Metastatic Melanoma at ASCO
5. Kosan Presents Preclinical Data on Nuclear Export Inhibitors, Novel Anticancer Agents, at AACR
6. Kosan Presents Preclinical Antitumor and Safety Data On Next-Generation Epothilone KOS-1803 at AACR
7. Kosan Presents Data on Cardiac Safety Profile of Hsp90 Inhibitor Tanespimycin (KOS-953) at AACR
8. Kosan Announces Data Presentations at Upcoming AACR Annual Meeting
9. Salix Pharmaceuticals Announces Positive Top Line Results of Balsalazide Tablets Registration Study
10. Inspiration Biopharmaceuticals Presents Data From Hemophilia Program at International Society On Thrombosis and Haemostasis (ISTH) Annual Meeting
11. Pieris Progresses Proprietary Asthma Program: Validation of Pulmonary Delivery of Anticalin-Based Protein Product Candidate
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/30/2014)... LONDON , Sept. 30, 2014 This report ... Million by the following Product Categories: Enteral Feeding Pumps, Nasogastric ... analytics for the US Canada, Japan , ... Latin America , and Rest of World. ... through 2018. Also, a six-year historic analysis is provided for ...
(Date:9/30/2014)... ROCKVILLE, Md. , Sept. 30, 2014 /PRNewswire/ ... natural way to modernize medicine, announced today the ... line of nutraceuticals developed to address men and ... staying healthy and vibrant into old age while ... line includes three condition-specific, whole-food and herb-based formulas, ...
(Date:9/30/2014)... NEW YORK , Sept. 30, 2014 /PRNewswire/ ... - 2014 Summary Global Markets Direct,s, ... 2014, provides an overview of the Aileron Therapeutics, ... report provides comprehensive information on the current therapeutic ... comparative analysis at various stages, therapeutics assessment by ...
Breaking Medicine Technology:Global Enteral Feeding Devices Industry 2Global Enteral Feeding Devices Industry 3Global Enteral Feeding Devices Industry 4Global Enteral Feeding Devices Industry 5Global Enteral Feeding Devices Industry 6Global Enteral Feeding Devices Industry 7Global Enteral Feeding Devices Industry 8Global Enteral Feeding Devices Industry 9Global Enteral Feeding Devices Industry 10Global Enteral Feeding Devices Industry 11Global Enteral Feeding Devices Industry 12Global Enteral Feeding Devices Industry 13Global Enteral Feeding Devices Industry 14Global Enteral Feeding Devices Industry 15Global Enteral Feeding Devices Industry 16Global Enteral Feeding Devices Industry 17Global Enteral Feeding Devices Industry 18Global Enteral Feeding Devices Industry 19Aileron Therapeutics, Inc. - Product Pipeline Review - 2014 2Aileron Therapeutics, Inc. - Product Pipeline Review - 2014 3
... (Ulleval,University Hospital, Oslo, Norway), lead investigator for the ... provide an update on,the study on Monday the ... be Sir Richard Peto (Professor of Medical,Statistics and ... University of Oxford) Professor Rory Collins (BHF Professor ...
... NEW YORK, July 17 The Michael J. ... in total funding to nine research teams under ... intellectual and financial,resources to help push potential PD ... nearly five million Parkinson,s patients,worldwide., "The discovery ...
Cached Medicine Technology:Michael J. Fox Foundation Awards $2.4 Million for Validation of Nine Promising Therapeutic Targets for Parkinson's Disease 2Michael J. Fox Foundation Awards $2.4 Million for Validation of Nine Promising Therapeutic Targets for Parkinson's Disease 3
(Date:10/1/2014)... protein beta-amyloid is strongly associated with Alzheimer,s disease; however, ... peptide is the causal agent of the onset and ... confirmation is that beta-amyloid is not harmful when found ... when it self-assembles to form the so-called amyloid fibrils ... beta-amyloid alone, but with multiple ones because each aggregate ...
(Date:10/1/2014)... Physical Sciences Research Council (EPSRC) will focus on ... systems which run, for example, manufacturing plants, power ... , The research will help understand and ... systems behind our critical national infrastructure. , ... (RITICS), based at Imperial College London, is co-ordinating ...
(Date:10/1/2014)... Familylifeinsurancequotes.org has released a new blog post explaining how ... Senior citizens can qualify for affordable term life insurance ... are over 50 years old. Some term life insurance ... , Term life insurance with a simplified issue can ... life insurance during retirement is important for covering funeral ...
(Date:10/1/2014)... Lifeinsurance-policy.com has released a new ... insurance prices for smokers. , Smoking will always have ... quotes is the best method to find affordable coverage. ... who need coverage. , Whole life insurance premiums ... policy. Since the coverage is permanent, the initial ...
(Date:10/1/2014)... FARMINGTON, Conn. (PRWEB) October 01, 2014 ... its company, including a redefined mission and visual ... the power of partnering with them to create ... more agile brand that focuses on empowering customers ... benefits communications. , The crown jewel of the ...
Breaking Medicine News(10 mins):Health News:Laying siege to beta-amyloid, the key protein in Alzheimer's disease 2Health News:£2.5 million to recognize and reduce cyber-attack threats to critical infrastructure 2Health News:Affordable Term Life Insurance - Senior Citizens Can Qualify for Coverage! 2Health News:Affordable Whole Life Insurance Premiums for Smokers! 2Health News:Farmington Company Launches Rebrand and New Positioning 2
... say on whether patients should have to opt in or ... is concerned that, in the proposed summary care record, data ... and this is not being made sufficiently clear to the ... letter to this week's journal. ,"Patients and clinicians ...
... care workers in the United States has risen, so ... ,According to Vanderbilt infectious disease experts Timothy ... should be provided to health care workers with latent ... test, particularly if they meet certain high-risk criteria. ...
... the debate with many others to discuss on the focus ... women.// Instead of giving a conceptual argument on the similarities ... and proved. ,Barres' experience as a female-to-male transgendered ... July 13 issue of Nature rebuking the comments of former ...
... A study led by Australian researchers has discovered a ... binding protein in human airway epithelial cells// that regulates ... researchers had explained in their study that the adipocyte/macrophage ... the uptake by fat cells of fatty acids and ...
... suicide fail to seek help from a doctor or mental ... may find it difficult to obtain adequate// treatment or medication, ... improve access to treatment for people with suicide ideation," said ... Los Angeles and study co-author. "There is a problem with ...
... published in the open access journal Substance Abuse Treatment, Prevention ... regular extra// training treats the alcohol dependent patients better for ... patients treated by trained GPs who abstain from drinking alcohol ... received the basic training alone at the medical school. ...
Cached Medicine News:Health News:Electronic Patient Record "Serious Threat" to Patient Confidentiality 2Health News:Transgender Experience - A Tool to Analyze Gender Difference By Stanford Scientist 2Health News:Transgender Experience - A Tool to Analyze Gender Difference By Stanford Scientist 3Health News:Transgender Experience - A Tool to Analyze Gender Difference By Stanford Scientist 4Health News:Study Says - Blocking 'aP2' Protein Prevents Airway Diseases 2Health News:Many Suicidal Adults Aren't Getting Mental Health Treatment 2
Dust covers for a variety of Zeiss microscopes...
These objectives have more contrast than the DLL objectives for enhanced contrast with tissue culture specimens. These objectives are designed for use on inverted microscopes and therefore their mark...
... Axiovert 40 inverted ... you have ever expected from a microscope in ... outstanding quality, and functionality. Axiovert 40 has been ... safe as possible thus increasing the efficiency ...
... TE2000E is an advanced inverted microscope for ... imaging ports, high resolution CFI60 optics, and ... imaging workstation. In addition, its super-nanoprecision z-axis ... is perfect for precise imaging in 3D. ...
Medicine Products: